Advaxis to Present at Upcoming March Conferences

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company (“Advaxis” or the “Company”) focused on the discovery, development and commercialization of cancer immunotherapies, announced today that Company management will present at the following upcoming March 2018 conferences:

Barclays Global Healthcare Conference

• Date and Time: Thursday, March 15, 2018 at 9:30am ET
• Venue: Loews Miami Beach Hotel, Miami, FL
• Presenter: Anthony Lombardo, Interim Chief Executive Officer
• Presentation: Company overview

25th Annual Future Leaders in the Biotech Industry Conference

• Date and Time: Friday, March 23rd at 3:00pm ET
• Venue: Millennium Broadway Hotel & Conference Center, New York, NY
• Presenter: Robert Petit, Ph.D., EVP and Chief Scientific Officer
• Presentation: Company overview

About Advaxis, Inc.

Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains integrate multiple functions into a single immunotherapy, and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and near-clinical development: HPV-associated cancers, individualized neoantigen immunotherapy, cancer-specific hotspot mutation immunotherapies and prostate cancer.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180313005417/en/

Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr. Director Corporate Communications and Government [e-mail]:Stern Strategy GroupBrian Hyland, [e-mail] Auerbach, [e-mail]:LHA Investor RelationsAnne Marie Fields, [e-mail]